Eisai is a Human health care (hhc) company that seeks to discover and develop innovative therapies that can help satisfy unmet medical needs and contribute to the health and well-being of people worldwide. Our hhc mission means that we regard patients and their families as the most important participants in the health care process and we are dedicated to helping improve their lives.

As the Indian pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., our key areas of commercial focus are neurology, oncology and metabolic diseases.

CNS

  • ARICEP 5
  • ARICEP 10
  • ARICEP 23 SR
  • ARICEP M
  • ARICEP M FORTE
  • ZONEGRAN
  • EPRISAN SR
  • EPRISAN D SR
  • FYCOMPA 2MG
  • FYCOMPA 4MG
  • FYCOMPA 6MG
  • OZMELT-D
  • PARIT 20MG
  • PARIT D

Oncology

  • HALAVEN
  • LENVIMA 4MG
  • LENVIMA 10MG
  • QUICOBAL
  • DC BEADS

Multiple Sclerosis

  • AVONEX PFS
  • AVONEX PEN
  • PLEGRIDY 125
  • PLEGRIDY 63/94 mcg
  • TECFIDERA 120
  • TECFIDERA 240
  • TYSABRI

** Product Information as on September 30, 2021.

Note: Methycobal is outlicensed to Wockhardt, India

Disclaimer - The product relatedinformation contained on this website is for educational purposes only and is not a substitute for the advice of the physician nor recommendation for any particular treatment plan. Please consult your physician before using any product mentioned on this website. For complete information onthe products please refer to full prescribing information.